BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23531031)

  • 1. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells.
    Pugliese M; Fortunati N; Germano A; Asioli S; Marano F; Palestini N; Frairia R; Boccuzzi G; Catalano MG
    Thyroid; 2013 Jul; 23(7):838-46. PubMed ID: 23531031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
    Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
    J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
    Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
    Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
    Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
    [No Abstract]   [Full Text] [Related]  

  • 9. Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
    Choi YJ; Lee JE; Ji HD; Lee BR; Lee SB; Kim KS; Lee IK; Chin J; Cho SJ; Lee J; Lee SW; Ha JH; Jeon YH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer.
    Liu L; Li D; Chen Z; Yang J; Ma Y; Cai H; Shan C; Lv Z; Zhang X
    Cell Physiol Biochem; 2017; 43(3):905-914. PubMed ID: 28957796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
    Furuya F; Shimura H; Suzuki H; Taki K; Ohta K; Haraguchi K; Onaya T; Endo T; Kobayashi T
    Endocrinology; 2004 Jun; 145(6):2865-75. PubMed ID: 14976143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
    Zarnegar R; Brunaud L; Kanauchi H; Wong M; Fung M; Ginzinger D; Duh QY; Clark OH
    Surgery; 2002 Dec; 132(6):984-90; discussion 990. PubMed ID: 12490845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene.
    Presta I; Arturi F; Ferretti E; Mattei T; Scarpelli D; Tosi E; Scipioni A; Celano M; Gulino A; Filetti S; Russo D
    BMC Cancer; 2005 Jul; 5():80. PubMed ID: 16029487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
    Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer.
    ElMokh O; Taelman V; Radojewski P; Roelli MA; Stoss A; Dumont RA; Dettmer MS; Phillips WA; Walter MA; Charles RP
    J Nucl Med; 2019 Jul; 60(7):917-923. PubMed ID: 30464041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors.
    Puppin C; D'Aurizio F; D'Elia AV; Cesaratto L; Tell G; Russo D; Filetti S; Ferretti E; Tosi E; Mattei T; Pianta A; Pellizzari L; Damante G
    Endocrinology; 2005 Sep; 146(9):3967-74. PubMed ID: 15919754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
    Cheng W; Liu R; Zhu G; Wang H; Xing M
    J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
    Kim KI; Kang JH; Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC
    J Nucl Med; 2007 Sep; 48(9):1553-61. PubMed ID: 17704247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells.
    Xu S; Cheng X; Wu J; Wang Y; Wang X; Wu L; Yu H; Bao J; Zhang L
    J Mol Cell Biol; 2022 Jan; 13(11):791-807. PubMed ID: 34751390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
    Kitazono M; Robey R; Zhan Z; Sarlis NJ; Skarulis MC; Aikou T; Bates S; Fojo T
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3430-5. PubMed ID: 11443220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.